Raymond Bass, MD
Nephrology · Wheaton, MDNPI 1689672164
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations.
Across 314 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$1K
- AstraZeneca$966
- Amgen$635
- Otsuka America Pharmaceutical, Inc.$603
- Bayer$599
- Akebia Therapeutics Inc$441
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,34395%
- Education$3555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 46 | $1,017 |
| AstraZeneca(2 entities) | 47 | $966 |
| Amgen(2 entities) | 29 | $635 |
| Otsuka America Pharmaceutical, Inc. | 32 | $603 |
| Bayer | 28 | $599 |
| Akebia Therapeutics Inc | 22 | $441 |
| Aurinia Pharma U.S., Inc. | 13 | $308 |
| Boehringer Ingelheim | 12 | $275 |
| Fresenius USA Marketing, Inc. | 13 | $253 |
| Calliditas Therapeutics US Inc. | 11 | $233 |
| Novartis | 10 | $219 |
| OPKO Pharmaceuticals, LLC | 9 | $218 |
| Travere Therapeutics, Inc. | 7 | $170 |
| Ardelyx, Inc. | 6 | $134 |
| GSK | 5 | $98 |
| Mallinckrodt Enterprises LLC | 3 | $77 |
| Novo Nordisk | 3 | $58 |
| Mallinckrodt Hospital Products Inc. | 2 | $53 |
| Apellis Pharmaceuticals, Inc. | 2 | $48 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Biomerieux Inc | 1 | $17 |
How this compares
$6,698 in reported general payments places this provider in the 85th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 184 | $195,856 |
| VeltassaPatiromer Calcium Sorbitex | 43 | $74,461 |
| JardianceEmpagliflozin | 46 | $67,774 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $14,059 |
| Sevelamer Carbonate | 56 | $10,087 |
| Potassium Citrate ErPotassium Citrate | 45 | $5,824 |
| ProsolParenteral Amino Acid 20% No.1 | 35 | $4,237 |
| Chlorthalidone | 119 | $4,020 |
| Eplerenone | 26 | $3,055 |
| Losartan Potassium | 287 | $2,832 |
| Spironolactone | 233 | $2,601 |
| Allopurinol | 201 | $2,363 |
| Calcium Acetate | 12 | $2,352 |
| Furosemide | 228 | $2,031 |
| Amlodipine Besylate | 237 | $1,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $966 | $209,915196 claims |
| Boehringer IngelheimJardiance | $275 | $67,77446 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $31 | $1,81227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 285 nephrology providers in Maryland.
Other nephrology in Wheaton
- Kiran SamindlaFrederick$491K
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
- Daniel BrennanBaltimore$133K
- Monika DhillonBaltimore$126K
- Duvuru GeethaBaltimore$91K
- Eli RozaHagerstown$79K
- Mohamed AttaBaltimore$65K
- Michelle EstrellaBaltimore$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.